Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Stuttgart – page 48

982 clinical trials in Stuttgart, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Stuttgart at a glance
982
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

982 trials in Stuttgart

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Empagliflozin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer extensive stage+2

Not recruiting

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:AIO-Studien gGmbH

Prostate cancer

Not recruiting

A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Triple negative breast cancer

Not recruiting

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Urticaria chronic

Not recruiting

Study of BLU-808 tablets compared to placebo in adults with chronic inducible urticaria and chronic spontaneous urticaria

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BLU-808
  • Sponsor:Blueprint Medicines Corp.

Bladder transitional cell carcinoma

Not recruiting

Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nogapendekin alfa inbakicept
  • Sponsor:Immunitybio Inc.

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Stuttgart

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer, diffuse large B-cell lymphoma, and bladder cancer treatments. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Advanced Cancer Treatments
  • Immunotherapy Studies
  • Novel Drug Combinations

Several trials investigating breakthrough treatments for various forms of leukemia and solid tumors.

02 Immunology and Vaccines

Research focusing on cytomegalovirus prevention and influenza vaccination in different age groups. Studies evaluate innovative vaccine formulations and immune responses.

  • Vaccine Development
  • Immune Response Studies
  • Preventive Medicine

Trials aim to enhance vaccine efficacy and improve protection against infectious diseases.

03 Metabolic and Eye Disorders

Studies addressing weight management and various eye conditions including retinal disorders. Research includes innovative treatments for macular degeneration and vision preservation.

  • Weight Management Therapies
  • Retinal Disease Treatment
  • Vision Preservation

Focus on developing treatments that improve patient outcomes and quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.